1. Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus. (May 2014) Authors: Takvorian, SU; Merola, JF; Costenbader, KH Other Names: Costenbader KH guest-editor.; Edwards CJ guest-editor. Journal: Lupus Issue: Volume 23:Number 6(2014) Page Start: 537 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. (July 2014) Authors: Merola, JF; Bermas, B; Lu, B; Karlson, EW; Massarotti, E; Schur, PH; Costenbader, KH Journal: Lupus Issue: Volume 23:Number 8(2014) Page Start: 778 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures. (4th May 2023) Authors: Skougaard, M; Stisen, ZR; Jørgensen, TS; Egeberg, A; Hansen, RL; Perez-Chada, LM; Mogensen, M; Merola, JF; Gerwien, JG; Kristensen, LE Journal: Scandinavian journal of rheumatology Issue: Volume 52:Number 3(2023) Page Start: 259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0112 In psoriatic arthritis fatigue is driven by inflammation, disease duration, and chronic pain: an observational danbio registry study. (15th June 2017) Authors: Skougaard, M; Jørgensen, TS; Rifbjerg-Madsen, S; Coates, L; Egeberg, A; Amris, K; Dreyer, L; Højgaard, P; Guldberg-Møller, J; Merola, JF; Frederiksen, P; Gudbergsen, H; Kristensen, LE Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial. (15th June 2017) Authors: Mease, PJ; Hall, S; FitzGerald, O; Heijde, D van der; Merola, JF; Avila-Zapata, F; Cieślak, D; Graham, D; Wang, C; Menon, S; Hendrikx, T; Kanik, KS Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le. (15th June 2017) Authors: Furie, R; Werth, VP; Merola, JF; Reynolds, TL; Stevenson, L; Wang, W; Smirnakis, K; Barbey, C; Musselli, C; Werneburg, B; Rabah, D; Franchimont, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 857 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0437 Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior tnf inadequate response. (15th June 2017) Authors: Kristensen, LE; Merola, JF; Dutz, J; Adams, DH; Kerr, L; Rich, P Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 937 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0461 Characterisation of different low disease activity measurements in patients with psoriatic arthritis. (15th June 2017) Authors: Coates, LC; Gottlieb, AB; Merola, JF; Aikman, L; Szumski, A; Chhabra, A Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 947 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗